Pre-cART elevation of CRP and CD4+ t-cell immune activation associated with HIV clinical progression in a multinational case-cohort study

Journal of Acquired Immune Deficiency Syndromes

Volumn 70, Issue 2, 2015, Pages 163-171

  Balagopal, Ashwin ^a   Asmuth, David M ^b   Yang, Wei Teng ^a   Campbell, Thomas B ^c   Gupte, Nikhil ^a   Smeaton, Laura ^d   Kanyama, Cecilia ^e   Grinsztejn, Beatriz ^f   Santos, Breno ^g   Supparatpinyo, Khuanchai ^h   Badal Faesen, Sharlaa ⁱ   Lama, Javier R ^j   Lalloo, Umesh G ^k   Zulu, Fatima ^l   Pawar, Jyoti S ^m   Riviere, Cynthia ⁿ   Kumarasamy, Nagalingeswaran ^o   Hakim, James ^p   Li, Xiao Dong ^p   Pollard, Richard B ^b   Semba, Richard D ^q   Thomas, David L ^a   Bollinger, Robert C ^a   Gupta, Amita ^a   more..

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF NORTH CAROLINA PROJECT   (Malawi)

^f Funda??o Oswaldo Cruz   (Brazil)

^g HOSPITAL NOSSA SENHORA DA CONCEIÇÃO   (Brazil)

^h CHIANG MAI UNIVERSITY   (Thailand)

ⁱ UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^j ASOCIACIÓN CIVIL IMPACTA SALUD Y EDUCACIÓN   (Peru)

^k UNIVERSITY OF KWAZULU NATAL   (South Africa)

^l UNIVERSITY OF MALAWI   (Malawi)

^m NATIONAL AIDS RESEARCH INSTITUTE   (India)

ⁿ Centers Institute of Infectious Diseases and Reproductive Health   (Haïti)

^o YRG CENTRE FOR AIDS RESEARCH AND EDUCATION   (India)

^p UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^q JOHNS HOPKINS UNIVERSITY   (United States)

more..

Author keywords

C reactive protein; cART clinical outcomes; Global HIV; Immune activation; T cell activation

Indexed keywords

ATAZANAVIR; BIOLOGICAL MARKER; C REACTIVE PROTEIN; DIDANOSINE; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; EMTRICITABINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HEMOGLOBIN; IMMUNOGLOBULIN M ANTIBODY; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; AREA UNDER THE CURVE; ASIAN; BLACK PERSON; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COHORT ANALYSIS; CONFERENCE PAPER; CONTROLLED STUDY; CREATININE CLEARANCE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; T LYMPHOCYTE ACTIVATION; CLINICAL TRIAL; DRUG COMBINATION; INTERNATIONAL COOPERATION; METABOLISM; MULTICENTER STUDY; PATHOLOGY; PHYSIOLOGY;

ADULT; ANTI-HIV AGENTS; BIOMARKERS; C-REACTIVE PROTEIN; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; INTERNATIONALITY; MALE;

EID: 84942024581     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000696     Document Type: Conference Paper

References (50)

1. Larson HJ, Bertozzi S, Piot P. Redesigning the AIDS response for longterm impact. Bull World Health Organ. 2011; 89: 846-852.
2. Gupta A, Nadkarni G, Yang WT, et al. Early mortality in adults initiating antiretroviral therapy (ART) in low- and middle-income countries (LMIC): a systematic review and meta-analysis. PLoS One. 2011; 6: e28691.
3. Poka-Mayap V, Pefura-Yone EW, Kengne AP, et al. Mortality and its determinants among patients infected with HIV-1 on antiretroviral therapy in a referral centre in Yaounde, Cameroon: a retrospective cohort study. BMJ Open. 2013; 3: e003210.
4. Lapadula G, Cozzi-Lepri A, Marchetti G, et al. Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment. AIDS. 2013; 27: 769-779.
5. Rodger AJ, Lodwick R, Schechter M, et al. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS. 2013; 27: 973-979.
6. Antiretroviral Therapy Cohort C; Shepherd BS, Jenkins CA, Parrish DD, et al. Higher rates of AIDS during the first year of antiretroviral therapy among migrants: the importance of tuberculosis. AIDS. 2013; 27: 1321-1329.
7. May M, Sterne JA, Sabin C, et al. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS. 2007; 21: 1185-1197.
8. Boulle A, Schomaker M, May MT, et al. Mortality in patients with HIV-1 infection starting antiretroviral therapy in South Africa, Europe, or North America: a collaborative analysis of prospective studies. PLoS Med. 2014; 11: e1001718.
9. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1- infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006; 367: 817-824.
10. Chene G, Sterne JA, May M, et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet. 2003; 362: 679-686.
11. Bagchi S, Kempf MC, Westfall AO, et al. Can routine clinical markers be used longitudinally to monitor antiretroviral therapy success in resourcelimited settings? Clin Infect Dis. 2007; 44: 135-138.
12. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002; 360: 119-129.
13. Fregonese F, Collins IJ, Jourdain G, et al. Predictors of 5-year mortality in HIV-infected adults starting highly active antiretroviral therapy in Thailand. J Acquir Immune Defic Syndr. 2012; 60: 91-98.
14. Helleberg M, Kronborg G, Larsen CS, et al. Poor CD4 response despite viral suppression is associated with increased non-AIDS-related mortality among HIV patients and their parents. AIDS. 2013; 27: 1021-1026.
15. Young J, Psichogiou M, Meyer L, et al. CD4 cell count and the risk of AIDS or death in HIV-infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE. PLoS Med. 2012; 9: e1001194.
16. Mocroft A, Furrer HJ, Miro JM, et al. The incidence of AIDS-defining illnesses at a current CD4 count $ 200 cells/mL in the post-combination antiretroviral therapy era. Clin Infect Dis. 2013; 57: 1038-1047.
17. Sodora DL, Silvestri G. Immune activation and AIDS pathogenesis. AIDS. 2008; 22: 439-446.
18. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006; 12: 1365-1371.
19. Ancuta P, Kamat A, Kunstman KJ, et al. Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS One. 2008; 3: e2516.
20. Balagopal A, Philp FH, Astemborski J, et al. Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology. 2008; 135: 226-233.
21. Sandler NG, Wand H, Roque A, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis. 2011; 203: 780-790.
22. Hunt PW, Martin JN, Sinclair E, et al. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis. 2003; 187: 1534-1543.
23. Redd AD, Dabitao D, Bream JH, et al. Microbial translocation, the innate cytokine response, and HIV-1 disease progression in Africa. Proc Natl Acad Sci U S A. 2009; 106: 6718-6723.
24. Campbell TB, Smeaton LM, Kumarasamy N, et al. Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings. PLoS Med. 2012; 9: e1001290.
25. Barlow WE, Ichikawa L, Rosner D, et al. Analysis of case-cohort designs. J Clin Epidemiol. 1999; 52: 1165-1172.
26. Onland-Moret NC, van der AD, van der Schouw YT, et al. Analysis of case-cohort data: a comparison of different methods. J Clin Epidemiol. 2007; 60: 350-355.
27. Balagopal A, Gama L, Franco V, et al. Detection of microbial translocation in HIV and SIV infection using the Limulus amebocyte lysate assay is masked by serum and plasma. PLoS One. 2012; 7: e41258.
28. Grinsztejn B, Smeaton L, Barnett R, et al. Sex-associated differences in pre-antiretroviral therapy plasma HIV RNA in diverse areas of the world vary by CD4(+) T-cell count. Antivir Ther. 2011; 16: 1057-1062.
29. Pedersen KK, Pedersen M, Gaardbo JC, et al. Persisting inflammation and chronic immune activation but intact cognitive function in HIVinfected patients after long-term treatment with combination antiretroviral therapy. J Acquir Immune Defic Syndr. 2013; 63: 272-279.
30. Carsenti-Dellamonica H, Saidi H, Ticchioni M, et al. The suppression of immune activation during enfuvirtide-based salvage therapy is associated with reduced CCR5 expression and decreased concentrations of circulating interleukin-12 and IP-10 during 48 weeks of longitudinal followup. HIV Med. 2011; 12: 65-77.
31. Jiao Y, Zhang T, Wang R, et al. Plasma IP-10 is associated with rapid disease progression in early HIV-1 infection. Viral Immunol. 2012; 25: 333-337.
32. Duong T, Jourdain G, Ngo-Giang-Huong N, et al. Laboratory and clinical predictors of disease progression following initiation of combination therapy in HIV-infected adults in Thailand. PLoS One. 2012; 7: e43375.
33. Smith CJ, Ryom L, Weber R, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D: A: D): a multicohort collaboration. Lancet. 2014; 384: 241-248.
34. Drain PK, Kupka R, Msamanga GI, et al. C-reactive protein independently predicts HIV-related outcomes among women and children in a resource-poor setting. AIDS. 2007; 21: 2067-2075.
35. Redd AD, Eaton KP, Kong X, et al. C-reactive protein levels increase during HIV-1 disease progression in Rakai, Uganda, despite the absence of microbial translocation. J Acquir Immune Defic Syndr. 2010; 54: 556-559.
36. Boulware DR, Hullsiek KH, Puronen CE, et al. Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J Infect Dis. 2011; 203: 1637-1646.
37. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008; 5: e203.
38. Rudy BJ, Lindsey JC, Flynn PM, et al. Immune reconstitution and predictors of virologic failure in adolescents infected through risk behaviors and initiating HAART: week 60 results from the PACTG 381 cohort. AIDS Res Hum Retroviruses. 2006; 22: 213-221.
39. Hunt PW, Cao HL, Muzoora C, et al. Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy. AIDS. 2011; 25: 2123-2131.
40. Taiwo B, Matining RM, Zheng L, et al. Associations of T cell activation and inflammatory biomarkers with virological response to darunavir/ritonavir plus raltegravir therapy. J Antimicrob Chemother. 2013; 68: 1857-1861.
41. Roine I, Arguedas A, Faingezicht I, et al. Early detection of sequelaprone osteomyelitis in children with use of simple clinical and laboratory criteria. Clin Infect Dis. 1997; 24: 849-853.
42. Mora S, Ridker PM. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)- can C-reactive protein be used to target statin therapy in primary prevention? Am J Cardiol. 2006; 97: 33a-41a.
43. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003; 107: 499-511.
44. Mildvan D, Bosch RJ, Kim RS, et al. Immunophenotypic markers and antiretroviral therapy (IMART): T cell activation and maturation help predict treatment response. J Infect Dis. 2004; 189: 1811-1820.
45. Ondoa P, Koblavi-Deme S, Borget MY, et al. Assessment of CD8 T cell immune activation markers to monitor response to antiretroviral therapy among HIV-1 infected patients in Cote d'Ivoire. Clin Exp Immunol. 2005; 140: 138-148.
46. Zhang JC, Zhang HJ, Li Y, et al. Changes in levels of T cell subpopulations to monitor the response to antiretroviral therapy among HIV-1-infected patients during two years of HIV-1 replication suppression. Scand J Infect Dis. 2013; 45: 368-377.
47. Kalayjian RC, Machekano RN, Rizk N, et al. Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy. J Infect Dis. 2010; 201: 1796-1805.
48. Rodger AJ, Fox Z, Lundgren JD, et al. Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. J Infect Dis. 2009; 200: 973-983.
49. Zeremski M, Markatou M, Brown QB, et al. Interferon gamma-inducible protein 10: a predictive marker of successful treatment response in hepatitis C virus/HIV-coinfected patients. J Acquir Immune Defic Syndr. 2007; 45: 262-268.
50. Marchetti G, Cozzi-Lepri A, Merlini E, et al. Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count. AIDS. 2011; 25: 1385-1394.